ASH 2023 | Challenges in treating patients with RAS-pathway activating mutations in ALL
Britta Vormoor
• 10 Dec 2023
Britta Vormoor, MD, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, discusses the challenges that remain in treating patients with RAS-pathway activating mutations in acute lymphoblastic leukemia (ALL). The biggest challenge is deciding where therapies targeting this pathway should be included in the treatment paradigm and how they will be evaluated against standardized treatment regimens. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
